BX-001N Part 1

Phase 2Small molecule

BBilix Co.,Ltd.

BX-001N Part 1 is one of 42 small molecule programs targeting Acute Kidney Injury. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Kidney InjuryActive, not recruiting

Acute Kidney InjuryPhase 2

Active, not recruiting

Competition

Competitive Landscape

178 competitors in Acute Kidney Injury

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Phase 3

3 2

Truphylline

TThe Searle Company Limited Pakistan

Phase 3

2 3

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

2 4

Crestor

AstraZeneca

Preclinical

3 5

L-Alanyl/l-Glutamine

TTemple Therapeutics BV

Phase 3

1 6

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 7

Celexa

AbbVie

Preclinical

1 8

Proamatine

Takeda

Preclinical

1 9

Lexapro

AbbVie

Preclinical

1 10

Lescol

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Ischemia Reperfusion Injury

NCT07164833

Clinical

Trials by Indication[1]

Tics1 trial

A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants

Completed·BBilix Co.,Ltd.·Phase 1·NCT06097702·51 enrolled

Ischemia Reperfusion Injury1 trial

Randomized, Single-blind, Multi-center, Placebo-controlled, Phase 2a Clinical Trial of BX-001N to Prevent From Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE)

Recruiting·BBilix Co.,Ltd.·Phase 2·NCT07164833·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BX-001N Part 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BX-001N Part 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BX-001N Part 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bilix Co.,Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBilix Co.,Ltd.

BX-001N Part 1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Tics1 trial

Ischemia Reperfusion Injury1 trial

References

Drug Info

Quick Facts

Related News